ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 Therapies

Stock Information for ENDRA Life Sciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About ENDRA Life Sciences Inc.

ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update
ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update
Study Highlighting ENDRA Life Sciences' TAEUS Technology in Patients with High BMI to be Presented at AASLD's The Liver Meeting® 2024
ENDRA Life Sciences Further Strengthens TAEUS® Platform Intellectual Property with Issuance of 17th European Patent
ENDRA Life Sciences Activates TAEUS System to Initiate Clinical Study at LMU University Hospital in Germany
ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements
ENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business Update
ENDRA Life Sciences Announces Reverse Stock Split

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.